- Home
- CAPR vs PSBD Comparison
CAPR vs PSBD Comparison
Compare CAPR & PSBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- PSBD
- Stock Information
- Founded
- CAPR 2005
- PSBD 2009
- Country
- CAPR United States
- PSBD United States
- Employees
- CAPR N/A
- PSBD N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- PSBD
- Sector
- CAPR Health Care
- PSBD
- Exchange
- CAPR Nasdaq
- PSBD Nasdaq
- Market Cap
- CAPR 324.6M
- PSBD 379.5M
- IPO Year
- CAPR N/A
- PSBD 2024
- Fundamental
- Price
- CAPR $4.66
- PSBD $12.04
- Analyst Decision
- CAPR Strong Buy
- PSBD Hold
- Analyst Count
- CAPR 6
- PSBD 5
- Target Price
- CAPR $23.17
- PSBD $13.70
- AVG Volume (30 Days)
- CAPR 1.9M
- PSBD 72.5K
- Earning Date
- CAPR 11-10-2025
- PSBD 11-05-2025
- Dividend Yield
- CAPR N/A
- PSBD 14.30%
- EPS Growth
- CAPR N/A
- PSBD N/A
- EPS
- CAPR N/A
- PSBD N/A
- Revenue
- CAPR $11,130,509.00
- PSBD N/A
- Revenue This Year
- CAPR N/A
- PSBD N/A
- Revenue Next Year
- CAPR $7,894.07
- PSBD N/A
- P/E Ratio
- CAPR N/A
- PSBD N/A
- Revenue Growth
- CAPR N/A
- PSBD N/A
- 52 Week Low
- CAPR $4.40
- PSBD $11.51
- 52 Week High
- CAPR $20.75
- PSBD $16.25
- Technical
- Relative Strength Index (RSI)
- CAPR 31.84
- PSBD 43.63
- Support Level
- CAPR $5.52
- PSBD $11.76
- Resistance Level
- CAPR $6.01
- PSBD $12.12
- Average True Range (ATR)
- CAPR 0.49
- PSBD 0.28
- MACD
- CAPR -0.06
- PSBD 0.01
- Stochastic Oscillator
- CAPR 12.42
- PSBD 32.95
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About PSBD Palmer Square Capital BDC Inc.
Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.